Xiqun Chen

Dr. Xiqun Chen


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XCXiqun Chen
Xiqun Chen
PWPauline Wales
Pauline Wales
LQLuisa Quinti
Luisa Quinti
FZFuxing Zuo
Fuxing Zuo
SMSébastien Moniot
Sébastien Moniot
AKAleksey G Kazantsev
Aleksey G Kazantsev
Sirtuin deacetylases regulate diverse cellular pathways and influence disease processes. Our previous studies identified the brain-enriched sirtuin-2 (SIRT2) deacetylase as a potential drug target to counteract neurodegeneration. In the present study, we characterize SIRT2 inhibition activity of the brain-permeable compound AK7 and examine the efficacy of this small molecule in models of Parkinson’s disease, amyotrophic lateral sclerosis and cerebral ischemia. Our results demonstrate that AK7 is neuroprotective in models of Parkinson’s disease; it ameliorates alpha-synuclein toxicity in vitro and prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopamine depletion and dopaminergic neuron loss in vivo. The compound does not show beneficial effects in mouse models of amyotrophic lateral sclerosis and cerebral ischemia. These findings underscore the specificity of protective effects observed here in models of Parkinson’s disease, and previously in Huntington’s disease, and support the development of SIRT2 inhibitors as potential therapeutics for the two neurodegenerative diseases.

26 October 2015 in Translational Neurodegeneration
Verified
Journal Article
Open access
PDF file
DFDanielle D. Feng
Danielle D. Feng
WCWaijiao Cai
Waijiao Cai
XCXiqun Chen
Xiqun Chen
Epidemiological studies support a general inverse association between the risk of cancer development and Parkinson’s disease (PD). In recent years however, increasing amount of eclectic evidence points to a positive association between PD and cancers through different temporal analyses and ethnic groups. This positive association has been supported by several common genetic mutations in SNCA, PARK2, PARK8, ATM, p53, PTEN, and MC1R resulting in cellular changes such as mitochondrial dysfunction, aberrant protein aggregation, and cell cycle dysregulation. Here, we review the epidemiological and biological advances of the past decade in the association between PD and cancers to offer insight on the recent and sometimes contradictory findings.

2 July 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
XZXinyuan Zhang
Xinyuan Zhang
DGDavid Guarin
David Guarin
NMNiyaz Mohammadzadehhonarvar
Niyaz Mohammadzadehhonarvar
XCXiqun Chen
Xiqun Chen
XGXIANG GAO
XIANG GAO
Objective To systematically review and qualitatively evaluate epidemiological evidence on associations between Parkinson’s disease (PD) and cancer via meta-analysis. Data sources MEDLINE via PubMed, Web of Science and EMBASE, until March 2021. Study selection Included were publications that (1) were original epidemiological studies on PD and cancer; (2) reported risk estimates; (3) were in English. Exclusion criteria included: (1) review/comments; (2) biological studies; (3) case report/autopsy studies; (4) irrelevant exposure/outcome; (5) treated cases; (6) no measure of risk estimates; (7) no confidence intervals/exact p values and (8) duplicates. Data extraction and synthesis PRISMA and MOOSE guidelines were followed in data extraction. Two-step screening was performed by two authors blinded to each other. A random-effects model was used to calculate pooled relative risk (RR). Main outcomes and measures We included publications that assessed the risk of PD in individuals with vs without cancer and the risk of cancer in individuals with vs without PD. Results A total of 63 studies and 17 994 584 participants were included. Meta-analysis generated a pooled RR of 0.82 (n=33; 95% CI 0.76 to 0.88; p<0.001) for association between PD and total cancer, 0.76 (n=21; 95% CI 0.67 to 0.85; p<0.001) for PD and smoking-related cancer and 0.92 (n=19; 95% CI 0.84 to 0.99; p=0.03) for non-smoking-related cancer. PD was associated with an increased risk of melanoma (n=29; pooled RR=1.75; 95% CI 1.43 to 2.14; p<0.001) but not for other skin cancers (n=17; pooled RR=0.90; 95% CI 0.60 to 1.34; p=0.60). Conclusions PD and total cancer were inversely associated. This inverse association persisted for both smoking-related and non-smoking-related cancers. PD was positively associated with melanoma. These results provide evidence for further investigations for possible mechanistic associations between PD and cancer. Prospero registration number CRD42020162103.

26 December 2016 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
XCXiqun Chen
Xiqun Chen
HCHongxiang Chen
Hongxiang Chen
WCWaijiao Cai
Waijiao Cai
MMMichael Maguire
Michael Maguire
BYBailiu Ya
Bailiu Ya
MSMichael A. Schwarzschild
Michael A. Schwarzschild

10 March 2020 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
QYQing Ye
Qing Ye
Ya WenYa Wen
Ya Wen
NANasser Al-Kuwari
Nasser Al-Kuwari
XCXiqun Chen
Xiqun Chen
Patients with Parkinson’s disease (PD) generally have reduced risk of developing many types of cancers, except melanoma - a malignant tumor of melanin-producing cells in the skin. For decades, a large number of epidemiological studies have reported that occurrence of melanoma is higher than expected among subjects with PD, and occurrence of PD is reciprocally higher than expected among patients with melanoma. More recent epidemiological studies further indicated a bidirectional association, not only in the patients themselves but also in their relatives. This association between PD and melanoma offers a unique opportunity to understand PD. Here we summarize epidemiological, clinical, and biological evidence in regard to shared risk factors and possible underlying mechanisms for these two seemingly distinct conditions.

22 August 2024 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
KRK. N. Rose
K. N. Rose
MZM. Zorlu
M. Zorlu
AFA. Fassini
A. Fassini
HLH. Lee
H. Lee
WCW. Cai
W. Cai
SGS. N. Gomperts
S. N. Gomperts
Paradoxically, cigarette smoking is associated with a reduced risk of Parkinson’s Disease (PD). This led us to hypothesize that carbon monoxide (CO) levels, which are constitutively but modestly elevated in smokers, might contribute to neuroprotection. Using rodent models of PD based on α-synuclein (αSyn) accumulation and oxidative stress, we show that low-dose CO mitigates neurodegeneration and reduces αSyn pathology. Oral CO administration activated signaling cascades mediated by heme oxygenase-1 (HO-1), which have been implicated in limiting oxidative stress, and in promoting αSyn degradation, thereby conferring neuroprotection. Consistent with the neuroprotective effect of smoking, HO-1 levels in cerebrospinal fluid were higher in human smokers compared to nonsmokers. Moreover, in PD brain samples, HO-1 levels were higher in neurons without αSyn pathology. Thus, CO in rodent PD models reduces pathology and increases oxidative stress responses, phenocopying possible protective effects of smoking evident in PD patients. These data highlight the potential for low-dose CO-modulated pathways to slow symptom onset and limit pathology in PD patients.